Zheng RH, Bai XJ, Zhang WW, Wang J, Bai F, Yan CP, James EA, Bose HS, Wang NP, Zhao ZQ
A pooled analysis of the STEP 1-3 trials (n=2,117 semaglutide 2.4 mg, n=1,262 placebo) reported GI adverse events in 72.9% of the semaglutide group versus 47.1% of placebo, with nausea (43.9% vs 16.1%), diarrhea (29.7% vs 15.9%), vomiting (24.5% vs 6.3%), and constipation (24.2% vs 11.1%) the most common categories
Nanoemulsified orlistat-embedded multi-unit pellet system (MUPS) with improved dissolution and pancreatic lipase inhibition
The discovery of G6PD crystal structures and subsequent analyses provided us with further insights into this enzyme deficiency, since specific mutations can now be plotted on a 3D position in the protein structure
the findings below come from BPC-157 research and self-reported community sources